Beam Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Beam Therapeutics

06/05/2025 13:10

Beam Therapeutics Inc BEAM.OQ reported a quarterly adjusted loss of $1.24​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of $-1.21.  The mean expectation of fifteen analysts for the quarter was for a loss of $1.21 per share. Wall Street expected results to range from $-1.47 to -94 cents per share.

Revenue rose 0.8% to $7.47 million from a year ago; analysts expected $14.87 million.

Beam Therapeutics Inc's reported EPS for the quarter was a loss of $1.24​.

The company reported a quarterly loss of $109.27 million.

Beam Therapeutics Inc shares had risen by 1.5% this quarter and lost 20.1% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 0.5% in the last three months.​

In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Beam Therapeutics Inc is $41.00

This summary was machine generated from LSEG data May 6 at 12:10 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-1.21
-1.24
Missed
Dec. 31 2024
-1.20
-1.09
Beat
Sep. 30 2024
-1.16
-1.17
Missed
Jun. 30 2024
-1.13
-1.11
Beat